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Background: We designed this study to quantify the effects of radiotherapy (RT) on bone density as a local
response in spinal bone metastases of women with breast cancer and, secondly, to establish bone density as an
accurate and reproducible marker for assessment of local response to RT in spinal bone metastases.
Methods: We retrospectively assessed 135 osteolytic spinal metastases in 115 women with metastatic breast cancer
treated at our department between January 2000 and January 2012. Primary endpoint was to compare bone
density in the bone metastases before, 3 months after and 6 months after RT. Bone density was measured in
Hounsfield units (HU) in computed tomography scans. We calculated mean values in HU and the standard
deviation (SD) as a measurement of bone density before, 3 months and 6 months after RT. T-test was used for
statistical analysis of difference in bone density as well as for univariate analysis of prognostic factors for difference
in bone density 3 and 6 months after RT.
Results: Mean bone density was 194.8 HU ± SD 123.0 at baseline. Bone density increased significantly by a mean of
145.8 HU ± SD 139.4 after 3 months (p = .0001) and by 250.3 HU ± SD 147.1 after 6 months (p < .0001). Women
receiving bisphosphonates showed a tendency towards higher increase in bone density in the metastases after
3 months (152.6 HU ± SD 141.9 vs. 76.0 HU ± SD 86.1; p = .069) and pathological fractures before RT were associated
with a significantly higher increase in bone density after 3 months (202.3 HU ± SD 161.9 vs. 130.3 HU ± SD 129.2;
p = .013). Concomitant chemotherapy (ChT) or endocrine therapy (ET), hormone receptor status, performance score,
applied overall RT dose and prescription of a surgical corset did not correlate with a difference in bone density after
RT.
Conclusions: Bone density measurement in HU is a practicable and reproducible method for assessment of local
RT response in osteolytic metastases in breast cancer. Our analysis demonstrated an excellent local response within
metastases after palliative RT.
Keywords: Bone density, Bone metastases, Breast cancer, Radiotherapy, Local response* Correspondence: harald.rief@med.uni-heidelberg.de
1Department of Radiation Oncology, University Hospital Heidelberg,
Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© 2015 Foerster et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Table 1 Cases characteristics
Age
Median 60 years
Range 32-88 years
n %
Karnofsky performance status
30-70% 40 29.6%
80-90% 95 70.3%
Histology
Invasive ductal 107 79.3%
Invasive lobular 28 20.7%
Receptor status positivity
ER (N = 34) 28 82.4%
PgR (N = 50) 40 80.0%
HER2 (N = 135) 39 28.9%
Site
Thoracic 99 73.3%
Lumbar 36 26.7%
Number of bone metastases
Solitary 59 43.7%
Multiple 76 56.3%
Treatment indications
Pain 69 51.1%
Instability 44 32.6%
Pathological fracture
Before RT 29 21.5%
After RT 8 5.9%
Surgical corset
During RT 82 60.7%
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The bone is the most common site for metastases in
women with breast cancer [1]. Bone metastases of the
spinal column are a major cause of morbidity and
reduced quality of life due to severe pain, pathological
fractures, spinal cord compression and hypercalcemia
[2,3]. Bone metastases require a multimodal treatment
approach including radiotherapy (RT), minimal invasive
surgery and systemic treatments such as bisphospho-
nates [4]. RT is the most common treatment method
[5,6], and its indications are typically pain, instability or
neurological symptoms due to spinal cord compression
[7]. The simultaneous delivery of RT and bisphospho-
nates may be beneficial for re-ossification of the bone
affected by osseous metastases [8-10]. Previously we
were able to show that RT is capable of promoting re-
ossification leading to increased stability of spinal bone
metastases [11-13]. Secondly, in a recent trial we were
able to show that the quantification of bone density
within metastases was an accurate and practicable
method to evaluate local response after RT [14]. The
aim of our current analysis was to quantify the effects of
RT on bone density in the metastatic bone in breast can-
cer patients with spinal bone metastases and to establish
bone density as a marker for assessment of local
response to RT.
Methods
We retrospectively assessed 135 osteolytic metastases of
the thoracic and lumbar vertebral column treated with
RT at our department between January 2000 and January
2012. The spinal bone metastases were found in 115
women with metastatic breast cancer. Patients’ data
were collected from the local cancer registry. Median
age was 60 years (range 32–88) and median Karnofsky
performance status (KPS) was 80% at first presentation.
Seventy-six patients (56.3%) had more than one spinal
bone metastasis. Cases characteristics are shown in
Table 1. The cases selected for this study were those
with available minimum follow-up computed tomog-
raphy (CT) scans for 3 months after RT. For patients
that underwent RT for several regions, each irradiated
region was regarded separately as an individual case and
in each region only the metastasis with the highest
degree of instability according to Taneichi et al. was
included in our study [15]. The primary endpoint of this
study was to compare bone density in the irradiated
metastasis before RT and 3 months as well as 6 months
after RT. Additionally we performed a reference meas-
urement of the bone density in the neighboring irradi-
ated vertebral body which was not affected by bone
metastases. Most patients were treated additionally with
bisphosphonates during RT (91.1%), which represents a
major bias for the assessment of treatment response inthe metastasis. Therefore, a bone density measurement
of uninvolved vertebral bodies was executed to detect
the increase by a systemic treatment. Bone density was
assessed in Hounsfield units (HU) by manual region of
interest (ROI) setting of the whole vertebral body for un-
involved bone and within metastases for involved bone
(Figure 1). The study was approved by the university’s
ethical committee (# S-513/2012).Radiotherapy
RT was planned as virtual simulation based on plan-
ning CT imaging and was delivered over a dorsal 6
MV photon filed. The planning target volume (PTV)
covered the affected vertebral bodies as well as the
ones directly above and below. Median prescribed total
dose was 30.0 Gy in 3.0 Gy single fractions. Treatment
characteristics are shown in Table 2.
Figure 1 Osteolytic thoracic spinal metastasis (A) before RT and (B) 3 months after RT as a basis for bone density measurement in HU
by manual ROI setting.
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We calculated mean values in HU and the standard
deviation (SD) as a measurement for bone density before
as well as 3 and 6 months after RT. Regarding statistical
analysis of difference in bone density as well as for uni-
variate analysis of prognostic factors for difference in
bone density at 3 and at 6 months after RT we calcu-
lated the equality of variances and used the t-test. As
possible prognostic factors we investigated systemic
therapy (chemotherapy (ChT) and endocrine therapy
(ET)) before/after RT, bisphosphonates after RT, treat-
ment indications (pain, stability), prescription of a surgi-
cal corset, irradiated area (lumbar vs. thoracic), number
of metastases (1 vs. >1), prescribed overall RT dose,
pathological fractures before/after RT and hormone re-
ceptor status (estrogen (ER), progesterone (PgR), Her-2/
neu (HER2)). A p-value ≤ 0.05 was considered statisticallyTable 2 Treatment of cases
n %
Radiotherapy (RT) (N = 133)
10 × 3 Gy 77 57.9%
14 × 2.5 Gy 20 15.1%
20 × 2 Gy 34 25.6%
Others 2 1.5%
Systemic therapy prior to RT
Chemotherapy 46 34.1%
Endocrine therapy 47 34.8%
Bisphosphonates 51 37.8%
Systemic therapy after RT
Chemotherapy 72 53.3%
Endocrine therapy (N = 30) 26 86.7%
Bisphosphonates 123 91.1.%significant. All statistical analyses were performed with
SAS software 9.1 (SAS Institute, Cary, NC, USA).
Results
The mean calculated size of the metastases was
431.3 mm2 ± SD 313.5 and the mean bone density in the
metastases was 194.8 HU ± SD 123.0 at initial assess-
ment. Three months after RT we observed a mean bone
density of 340 HU ± SD 179.2 and after 6 months a
mean bone density of 433.1 HU ± SD 172.6 in the metas-
tases. Whereas mean bone density in the irradiated
unaffected neighboring vertebral bodies was 235.9 HU ±
SD 143.4 before RT, 228.6 HU ± SD 143.2 after 3 months
and 250.3 HU ± SD 147.1 after 6 months. Bone density
increased significantly in the metastases during follow-
up after RT. At 3 months the bone density had increased
by a mean of 145.8 HU ± SD 139.4 (p < .0001) and after
6 months by a mean of 238.0 HU ± SD 149.2 (p < .0001).
The bone density in the irradiated unaffected neighbor-
ing vertebral bodies used for reference measurements
did not change significantly during follow-up after RT.Table 3 Bone density (HU) in metastases and in irradiated
uninvolved bone
Mean SD Mean difference SD p-value
Bone metastases
Before RT 194.8 123.0
After 3 months 340.6 179.2 145.8 139.4 p < .0001
After 6 months 433.1 172.6 238.0 149.2 p < .0001
Irradiated
uninvolved bone
Before RT 235.9 143.4
After 3 months 228.6 143.2 −7.3 −1.41 p = .162
After 6 months 250.3 147.1 −0.1 −0.01 p = .993
Table 4 Univariate analysis of prognostic factors for difference in bone density in HU
After 3 months After 6 months
n Mean SD p-value n Mean SD p-value
Bisphosphonates after RT p = .069 p = .162
Yes 123 152.6 141.9 76 245.8 151.5
No 12 76.0 86.1 9 171.9 114.4
Pathological fracture before RT p = .013 p = .801
Yes 29 202.3 161.9 21 230.8 141.7
No 106 130.3 129.2 64 240.3 152.6
Pathological fracture after RT p = .399 p = .399
Yes 8 186.3 133.6 8 280.5 135.3
No 127 143.2 139.9 77 233.5 150.7
Chemotherapy before RT p = .946 p = .991
Yes 46 144.7 135.3 23 238.3 172.9
No 89 146.4 148.6 62 237.8 140.9
Chemotherapy after RT p = .741 p = .547
Yes 72 149.5 130.9 45 247.2 144.9
No 63 141.5 149.5 40 227.5 154.9
Endocrine therapy before RT p = .211 p = .133
Yes 47 125.2 137.3 25 200.2 136.1
No 88 156.8 140.1 60 253.7 152.6
Endocrine therapy after RT p = .536 p = .657
Yes 26 121.9 98.1 17 196.3 143.6
No 4 87.8 125.4 2 250.0 316.8
Pain as indication for RT p = .822 p = .963
Yes 69 148.5 141.5 46 238.7 143.3
No 66 143.0 138.3 39 237.1 157.7
Instability as indication for RT p = .479 p = .554
Yes 91 139.9 133.9 57 231.2 141.9
No 44 158.1 150.9 28 251.7 164.8
Surgical corset p = .358 p = .213
Yes 82 136.9 134.9 52 221.8 144.6
No 53 159.6 146.3 33 263.4 154.9
Spine p = .437 p = .858
Thoracic 99 150.7 149.1 65 239.6 155.9
Lumbar 36 132.3 109.2 20 232.7 128.1
Number of metastases p = .983 p = .382
1 59 146.1 132.4 35 254.9 158.2
>1 76 145.6 145.5 50 226.1 142.9
Overall dose p = .886 p = .654
<=30 Gy 79 145.1 130.9 57 229.6 143.8
>30 Gy 54 141.6 150.8 26 245.6 162.9
KPS p = .815 p = .412
</=70% 40 150.1 148.1 23 263.4 259.9
>70% 95 143.9 136.4 62 228.5 163.7
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Table 4 Univariate analysis of prognostic factors for difference in bone density in HU (Continued)
Estrogen receptor status p = .278 p = .828
Positive 28 139.9 115.2 19 222.5 156.6
Negative 6 83.8 99.3 2 250.0 316.8
Progesterone receptor status p = .088 p = .694
Positive 40 159.9 123.5 25 242.7 149.5
Negative 10 87.8 83.4 4 276.5 214.5
Her-2/neu receptor status p = .581 p = .379
Positive 39 156.3 118.4 28 220.2 108.2
Negative 96 141.5 147.5 57 246.7 165.8
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−7.3 HU ± SD 60.4 (p = .162) and after 6 months, with a
mean decrease of −0.1 HU ± SD 70.1 (p = .993), there
was practically no change in bone density observable
(Table 3).
Increase in bone density of the metastases seemed to
be associated with the prescription of bisphosphonates.
While women receiving bisphosphonates had a mean
increase in bone density of 152.59 HU ± SD 141.99 in
the metastases after 3 months, patients without bispho-
sphonates only had a mean increase in bone density of
76.03 HU ± SD 86.6 (p = .069) in the metastases 3 months
following RT. Additionally we found that women with
pathological fractures before RT (21.5%) had a signifi-
cantly higher increase in bone density after 3 months
than those which presented without fractures at initial
assessment (202.3 HU ± SD 161.88 vs. 130.33 HU ± SD
129.23; p = .013). These differences were no longer de-
tectable 6 months after RT. All other investigated poten-
tially prognostic factors, especially concomitant ChT or
ET, hormone receptor status, KPS, applied overall dose
as well as the prescription of a surgical corset, did not
significantly correlate with an increase or decrease in
bone density after RT (Table 4).
Discussion
In previous studies we demonstrated that RT is capable
of improving stability in spinal bone metastases by facili-
tating re-ossification [11-14]. With our current analysis
we were able to quantify the re-ossification after RT by
measuring the change in mean bone density on the basis
of x-ray absorption in CT scans and we found that mean
bone density, as a local response, increased significantly
in the metastases after RT. While mean bone density in
the metastases increased by 145.8 HU ± SD 139.4 after
3 months (p < .0001) and by 238.0 HU ± SD 149.2 after
6 months (p < .0001), this was not the case in the irradi-
ated neighboring vertebrae unaffected by bone metasta-
ses. Other investigators found bone density to increase
after RT as well [16,17]. Currently local response is
chiefly assessed by visual judgment of sclerosis of theosteolytic lesions in CT scans, with complete response
being classified as complete sclerosis of the metastasis,
partial response as >50% regression of the metastasis
and no response as an unchanged metastases [18]. Such
an evaluation of local treatment response is very subject-
ive and imprecise. We believe bone density measure-
ment to be a more reliable and reproducible method for
assessment and quantification of re-ossification as a local
response to RT in osteolytic spinal bone metastases.
Clinical and preclinical studies suggest a benefit from
combined treatment with systemic bisphosphonates con-
comitant to RT [19-21] since they have been shown to
exhibit cytotoxic and radiosensitizing effects when com-
bined with RT additional to their anti-bone-resorptive
properties [22,23]. In our analysis there was a strong
tendency towards statistical significance for increased
bone density in the metastases with concomitant bis-
phosphonate treatment 3 months following RT (p = .069)
and after 6 months the mean increase in mean bone
density was still larger in patients receiving combination
treatment compared to those without bisphosphonates
(245.8 HU ± SD 151.5 vs. 171.9 HU ± SD 114.4). Never-
theless, the rate of bisphosphonates was high (91.1%).
However, this was not the case for the irradiated bone
unaffected by metastases. We believe that bisphospho-
nates may be capable of facilitating RT effects in bone
metastases and that these patients may respond more
rapidly. Other concomitant systemic treatments in the
form of ChT or ET did not affect bone density in our
analysis. Similarly, systemic treatment before/after RT
did not influence local response in terms of stability in
two earlier studies [12,13]. This is probably due to the
fact that most patients in our study were already post-
menopausal and did received bisphosphonates which was
not the case in another previous study where ChT before
RT had a negative effect on stability as a local response
to RT [11]. Negative effects on bone density by aromatase
inhibitors [24] and disturbances in bone remodeling by
ChT [25] may have been compensated by concomitant
bisphosphonate therapy, tamoxifen treatment probably
had a rather bone-protective effect [26] and ChT-
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in our cohort.
Furthermore we found that mean bone density increase
after 3 months was significantly higher in patients with
pathological fractures at initial assessment (p = .013)
which can be explained by physiological consolidation
processes with callus formation after acute fractures.
Nevertheless, pathological fracture may affect the bone
density in sintered vertebral body after treatment, but this
bias was insignificant small in 5.9% of patients.
We found no statistically significant correlation be-
tween the remaining investigated prognostic factors and
an increase or decrease in bone density after RT. Koswig
and Budach found bone density after 6 months to have
increased by 173% after 30 Gy in 10 fractions compared
to 120% after a single fraction of 8 Gy [16]. Most women
in our analysis were treated with an overall dose of
30 Gy in 3 Gy single fractions and thus we were unable
to detect any differences between fractionation sched-
ules. KPS and the prescription of a surgical corset also
did not affect response to RT in terms of bone density
although a higher KPS and not wearing a surgical corset
should in theory be associated with more physical activ-
ity which in turn can lead to an improved stability of
spinal bone metastases [11,14].Conclusions
Bone density increased significantly in the metastases
during follow-up after RT, while practically no change
was seen in the irradiated bone unaffected by metasta-
ses. Bone density measurement in HU is a reliable and
reproducible method for assessment of local response in
osteolytic metastases after RT. Concomitant bisphospho-
nate may protect from bone-resorptive effects induced
by ChT and ET.
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